Close mobile menu×
Close mobile menu

Joel E. Lavine, MD, PhD

Board Certifications: 
Pediatric Transplant Hepatology, Pediatric Gastroenterology
Accepting New Patients
Treats Children
Profile Headshot

Appointments

Book Online

Participating DocASAP doctors have online booking available without the need for a myColumbiaDoctors account.

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Pediatric Transplant Hepatology
  • Pediatric Gastroenterology

Clinical Expertise

  • Biliary Disease
  • Pancreatic Disease
  • Inflammatory Bowel Diseases (IBD)
  • Celiac Disease
  • Endoscopic Feeding Tube Placement
  • Pediatric Gastrointestinal (GI) Endoscopy
  • Pediatric Short Bowel Syndrome
  • Pediatric Inflammatory Bowel Disease (IBD)
  • Fatty Liver Disease, Non-Alcoholic
  • Pediatric Liver Disease-Chronic
  • Pediatric Liver Transplant
  • Pediatric Liver Disease-Acute
  • Liver Fibrosis
  • Hepatitis

Education & Training

  • University of California San Diego School of Medicine
  • Residency: University of California-San Francisco Medical Center
  • Fellowship: University of California-San Francisco Medical Center

About Joel Lavine

Dr. Joel Lavine is Chief of Pediatric Gastroenterology, Hepatology, and Nutrition at New York-Presbyterian/ Morgan Stanley Children’s Hospital. A noted physician-scientist, Dr. Lavine is both Vice Chair and Professor of Pediatrics at Columbia University Medical Center who has devoted his career to helping children with digestive health diseases.

Dr. Lavine earned his doctorate in molecular biology in 1980 at the University of California, Santa Barbara, and his medical degree from the University of California, San Diego, in 1984. He trained as a resident in Pediatrics and a fellow in pediatric gastroenterology at the University of California, San Francisco. He went on to join the faculties as an Assistant Professor at the University of California, San Francisco, and then Harvard Medical School before becoming Professor and Vice-Chairman for 15 years at the University of California, San Diego. He also served as Chief of Pediatric Gastroenterology, Hepatology and Nutrition there for 15 years.

Dr. Lavine’s research is in the treatment, natural history, etiopathogenesis, and genetics of fatty liver disease and viral hepatitis in children. He is investigating the role of sex steroid hormones on disease development, and the identification of genetic susceptibility loci. He is also developing noninvasive methods for assessing hepatic inflammation and cellular injury and looking at serum markers to determine more benign or aggressive forms of disease. He serves as National Chair of the NIH Clinical Research Network on this disease, and serves as Chair of multiple NIH study sections, workshops, advisory groups and Data and Safety Monitoring Boards.

In the clinical realm, Dr. Lavine sees gastroenterology patients in the outpatient setting for conditions such as celiac disease, inflammatory bowel disease, chronic malabsorption syndromes, and functional bowel disorders.

Academic Titles

  • Professor of Pediatrics (in the Institute of Human Nutrition)

Administrative Positions

  • Chief, Division of Pediatric Gastroenterology, Hepatology, and Nutrition

Committee/Societies/Council Memberships

American Association for the Study of Liver Diseases (AASLD)-Fellow

American Gastroenterological Association

American Pediatric Society

Society for Pediatric Research

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Morgan Stanley Children's Hospital

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

TRICARE

  • TRICARE

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
3959 Broadway
BHS 7-702 (Central)
New York, New York 10032
Phone:
(212) 305-5903
Fax:
(212) 342-5756
Primary
2
21 West 86th Street
New York, New York 10024
Phone:
(212) 305-5903

Research

The equivalent of this is foie gras. You have to force feed ducks to get fatty liver, but people seem to be able to develop it on their own. (The New York Times, Quotation of the Day for Saturday, June 14, 2014)

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in North America and globally. NAFLD is believed to be the hepatic component of metabolic syndrome, consisting of obesity, hypertension, dyslipidemia, and insulin resistance. There is currently no noninvasive methods of assessment for certain key components of NAFLD that requires a liver biopsy. There are also no currently FDA-approved therapies for treatment. Dr. Lavine has served as Co-Chair of the Steering Committee for NIH-funded national Nonalcoholic Steatohepatitis Clinical Research Network for the past 15 years, since inception. The Network strives to develop noninvasive imaging and serum biomarker surrogates to biopsy, to trial promising therapies, elucidate the pathophysiology and natural history of the disease, and to distinguish genetic, epigenetic and environmental susceptibilities to acquisition and progression of disease.

Research Interests

  • Fatty liver diseases in adults and children
  • Viral hepatitis
  • Inborn metabolic errors of the liver
  • Faculty and fellow development

Clinical Trials

Recruiting:

NCT02566889  A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease

NCT03467217 Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD)

Completed:

NCT00799578 A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

Grants

OPEN LABEL RANDOMIZED MULTICENTER STUDY TO ASSESS THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE, SAFETY, AND TOLERABLITY OF TWO DOSE LEVELS OF ELAFIBRANOR IN CHILDREN AND ADOLESCENTS, 8-17 YEEARS OF AGE WITH NASH (P&S Industry Clinical Trial)

Apr 4 2019 - Apr 4 2024

AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE AND MULTIPLE INTRAVENOUS DOSES OF PANTOPRAZOLE IN TWO AGE COHORTS OF HOSPITALIZED PEDIATRIC SUBJECTS 1 TO 16 YEARS OF AGE WHO ARE CANDIDATES FOR ACID SUPPRESSION THERAPY (P&S Industry Clinical Trial)

Nov 16 2017 - Nov 16 2022

EPIGENTIC MARKERS OF SEVERITY IN NONALCOHOLIC FATTY LIVER DISEASE (Federal Gov)

Aug 1 2018 - Jul 31 2021

CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

Jul 1 2016 - May 31 2021

CLINICAL RESEARCH ON NONALCOHOLIC FATTY LIVER DISEASE (Federal Gov)

Jul 1 2014 - Jun 30 2020

A MULTICENTER, PROSPECTIVE, LONGTERM, OBSERVATIONAL REGISTRY OF PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Private)

Nov 23 2015 - Nov 22 2019

I-ACT FOR CHILDREN, GLOBAL PEDIATRICS CLINICAL TRIALS NETWORK (Federal Gov)

Sep 1 2018 - Aug 31 2019

LOSARTAN FOR THE TREATMENT OF PEDIATIRC NAFLD: A PHASE 2 RANDOMIZED, PLACEBO-CONTROLLEDTRIAL (STOP-NAFLD). (Federal Gov)

Jul 1 2017 - Jun 30 2018

EPIGENTIC MARKERS OF SEVERITY IN NONALCOHOLIC FATTY LIVER DISEASE (Federal Gov)

Sep 23 2016 - Nov 30 2017

A MULTICENTER, PROSPECTIVE, LONG-TERM, OBSERVATIONAL REGISTR Y OF PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE. (Private)

Nov 23 2011 - Nov 22 2016

ADVANCED/TRANSPLANT HEPATOLOGY FELLOWHSIP PROGRAM (Private)

Jul 1 2013 - Jun 30 2014

PEDATRIC ADVERSE DRUG REACTIONS IN NASH (Federal Gov)

Mar 1 2013 - Nov 30 2013

THE PROTECT STUDY (Federal Gov)

Sep 1 2012 - Apr 30 2013

Selected Publications

Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston J, Loomba R, Brunt EM, Chen YI, Goodarzi M, Taylor KD, Yates KP, Tonascia J, Rotter J. Genome wide associations related to the spectrum of histologic features in nonalcoholic fatty liver disease in Hispanic boys. 2017. J. Pediatr. 190: 100-107. PMID: 28918882

Elbel E, Lavine JE, Downes M, Van Natta M, Yu R, Schwimmer JB, Behling C, Brunt E, Tonascia JT, Evans RM. Hepatic nuclear receptor expression associates with features of histology in pediatric nonalcoholic fatty liver disease. Hepatology Communications. 2018. In press.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston J, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR for the Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA. 2011. 305(16): 1659-1668. PMID 21521847

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Chalasani N, Dasarthy S, Diehl AM, Hameed B, Kowdley K, McCullough A, Clark J, Tonascia J, Brunt EM, Kleiner DE, Doo E for the NASH CRN.  Farnesoid-X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitits (FLINT): a multicentre, randomized, placebo-controlled trial.  Lancet. 2015. 385(9972): 956-65. PMID 25468160.

Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos S, Kohli R, Barlow S, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt E, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E, NASH CRN.  In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores.  Gastroenterology. 2016. 151(6): 1141-1154. PMID: 27569726

Sanyal AJ, Chalasani N, Kowdley K, McCullough A, Diehl AM, Bass N, Neuschwander-Tetri B, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt E, Kleiner D, Hoofnagle J, Robuck P, NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 2010.  New Engl J Med.  2010. 362: 1675-1685. PMID 20427778.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella, M, Harrison S, Brunt E, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018.  67(1): 328-357. PMID: 28714183

Woo Baidal J, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Science Translational Medicine. 2016. 8 (323): 323rv1. PMID: 26819197